SOURCE: BioMedReports


February 08, 2010 08:14 ET

MedaSorb's (MSBT.OB) Answer to Unmet Medical Need Could Be Commercialized This Year

LOS ANGELES, CA--(Marketwire - February 8, 2010) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that MedaSorb Technologies' (OTCBB: MSBT) flagship product CytoSorb™ -- a therapeutic device, may be a Holy Grail which has eluded medicine for decades.

Severe sepsis is a life-threatening condition, which affects over 18 million people each year.

"Unfortunately, most know someone who had developed a severe infection. It could have been something as catastrophic as a ruptured appendix, or something more common as pneumonia, maybe a bad urinary tract infection or even influenza -- where the infection got out of hand and sent that person to the intensive care unit on life support, with failing critical organs like the hearts, lungs, and kidneys," says Dr. Phillip Chan, MD, PhD, the Chief Executive Officer of the company.

"Despite the best medical care here in the United States, one in every three patients die of this disease, and in fact, more people die of severe sepsis in the United States than from either heart attacks or strokes or any single form of cancer. It remains a major unmet medical need."

While massive resources have been invested in developing and evaluating potential therapies, MedaSorb is conducting human trials in Europe and has already announced preliminary positive proof of concept in humans, using CytoSorb™ to treat severe sepsis patients.

"Our major goal (for 2010) is the successful completion of our trial, which will hopefully lead to CE Mark approval," Chan said.

The complete report is available now at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies. See our complete disclosure statements at BioMedReports.

For more biomedical sector and investment news go to

Contact Information

  • Media Contact:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556